Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone

John D. Del Rowe; Jacqueline Bello; Robin Mitnick; Brij Sood; Christopher Filippi; Justin Moran; Katherine Freeman; Frances Mendez; Robert Bases

doi:10.1016/S0360-3016(98)00374-5

Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone

John D. Del Rowe, Jacqueline Bello, Robin Mitnick, Brij Sood, Christopher Filippi, Justin Moran, Katherine Freeman, Frances Mendez, Robert Bases

Radiology

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Purpose: To determine if lucanthone crossed the blood-brain barrier in experimental animals; and to determine accelerated tumor regression of human brain metastases treated jointly with lucanthone and whole brain radiation. Methods and Materials: The organ distribution of ³H lucanthone in mice and ¹²⁵I lucanthone in rats was determined to learn if lucanthone crossed the blood-brain barrier. Size determinations were made of patients' brain metastases from magnetic resonance images or by computed tomography before and after treatment with 30 Gy whole brain radiation alone or with lucanthone. Results: The time course of lucanthone's distribution in brain was identical to that in muscle and heart after intraperitoneal or intravenous administration in experimental animals. Lucanthone, therefore, readily crossed the blood-brain barrier in experimental animals. Conclusion: Compared with radiation alone, the tumor regression in patients with brain metastases treated with lucanthone and radiation was accelerated, approaching significance using a permutation test at p = 0.0536.

Original language	English (US)
Pages (from-to)	89-93
Number of pages	5
Journal	International Journal of Radiation Oncology Biology Physics
Volume	43
Issue number	1
DOIs	https://doi.org/10.1016/S0360-3016(98)00374-5
State	Published - Jan 1999

Keywords

Blood-brain barrier
Lucanthone
Topoisomerase II

ASJC Scopus subject areas

Radiation
Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0360-3016(98)00374-5

Cite this

Del Rowe, J. D., Bello, J., Mitnick, R., Sood, B., Filippi, C., Moran, J., Freeman, K., Mendez, F., & Bases, R. (1999). Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. International Journal of Radiation Oncology Biology Physics, 43(1), 89-93. https://doi.org/10.1016/S0360-3016(98)00374-5

Del Rowe, JD, Bello, J, Mitnick, R, Sood, B, Filippi, C, Moran, J, Freeman, K, Mendez, F & Bases, R 1999, 'Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone', International Journal of Radiation Oncology Biology Physics, vol. 43, no. 1, pp. 89-93. https://doi.org/10.1016/S0360-3016(98)00374-5

@article{1d785be7c1b3480fbdb3ed63ff5ad908,

title = "Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone",

abstract = "Purpose: To determine if lucanthone crossed the blood-brain barrier in experimental animals; and to determine accelerated tumor regression of human brain metastases treated jointly with lucanthone and whole brain radiation. Methods and Materials: The organ distribution of 3H lucanthone in mice and 125I lucanthone in rats was determined to learn if lucanthone crossed the blood-brain barrier. Size determinations were made of patients' brain metastases from magnetic resonance images or by computed tomography before and after treatment with 30 Gy whole brain radiation alone or with lucanthone. Results: The time course of lucanthone's distribution in brain was identical to that in muscle and heart after intraperitoneal or intravenous administration in experimental animals. Lucanthone, therefore, readily crossed the blood-brain barrier in experimental animals. Conclusion: Compared with radiation alone, the tumor regression in patients with brain metastases treated with lucanthone and radiation was accelerated, approaching significance using a permutation test at p = 0.0536.",

keywords = "Blood-brain barrier, Lucanthone, Topoisomerase II",

author = "{Del Rowe}, {John D.} and Jacqueline Bello and Robin Mitnick and Brij Sood and Christopher Filippi and Justin Moran and Katherine Freeman and Frances Mendez and Robert Bases",

note = "Funding Information: This work was supported by The Rome Sisters Foundation.",

year = "1999",

month = jan,

doi = "10.1016/S0360-3016(98)00374-5",

language = "English (US)",

volume = "43",

pages = "89--93",

journal = "International Journal of Radiation Oncology Biology Physics",

issn = "0360-3016",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone

AU - Del Rowe, John D.

AU - Bello, Jacqueline

AU - Mitnick, Robin

AU - Sood, Brij

AU - Filippi, Christopher

AU - Moran, Justin

AU - Freeman, Katherine

AU - Mendez, Frances

AU - Bases, Robert

N1 - Funding Information: This work was supported by The Rome Sisters Foundation.

PY - 1999/1

Y1 - 1999/1

N2 - Purpose: To determine if lucanthone crossed the blood-brain barrier in experimental animals; and to determine accelerated tumor regression of human brain metastases treated jointly with lucanthone and whole brain radiation. Methods and Materials: The organ distribution of 3H lucanthone in mice and 125I lucanthone in rats was determined to learn if lucanthone crossed the blood-brain barrier. Size determinations were made of patients' brain metastases from magnetic resonance images or by computed tomography before and after treatment with 30 Gy whole brain radiation alone or with lucanthone. Results: The time course of lucanthone's distribution in brain was identical to that in muscle and heart after intraperitoneal or intravenous administration in experimental animals. Lucanthone, therefore, readily crossed the blood-brain barrier in experimental animals. Conclusion: Compared with radiation alone, the tumor regression in patients with brain metastases treated with lucanthone and radiation was accelerated, approaching significance using a permutation test at p = 0.0536.

AB - Purpose: To determine if lucanthone crossed the blood-brain barrier in experimental animals; and to determine accelerated tumor regression of human brain metastases treated jointly with lucanthone and whole brain radiation. Methods and Materials: The organ distribution of 3H lucanthone in mice and 125I lucanthone in rats was determined to learn if lucanthone crossed the blood-brain barrier. Size determinations were made of patients' brain metastases from magnetic resonance images or by computed tomography before and after treatment with 30 Gy whole brain radiation alone or with lucanthone. Results: The time course of lucanthone's distribution in brain was identical to that in muscle and heart after intraperitoneal or intravenous administration in experimental animals. Lucanthone, therefore, readily crossed the blood-brain barrier in experimental animals. Conclusion: Compared with radiation alone, the tumor regression in patients with brain metastases treated with lucanthone and radiation was accelerated, approaching significance using a permutation test at p = 0.0536.

KW - Blood-brain barrier

KW - Lucanthone

KW - Topoisomerase II

UR - http://www.scopus.com/inward/record.url?scp=0032943024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032943024&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(98)00374-5

DO - 10.1016/S0360-3016(98)00374-5

M3 - Article

C2 - 9989518

AN - SCOPUS:0032943024

SN - 0360-3016

VL - 43

SP - 89

EP - 93

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

IS - 1

ER -

Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this